Text Size

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components

Pfeiffer N., Traverso C.E., Lorenz K., Saarela V., Liinamaa J., Uusitalo H., Astakhov Y., Boiko E., Ropo A.


  • 2014
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Mainz University Medical Center, Langenbeckstr. 1, Mainz, 55101, Germany; Clinica Oculistica, Di.N.O.G.M.I., University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy; Department of Ophthalmology, Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland; Department of Ophthalmology, University of Tampere and TAUH Eye Center, Tampere, Finland; First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Santen Oy, Clinical Research and Medical Affairs, Helsinki, Finland

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.


Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.


Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022